| Literature DB >> 26225130 |
Krzysztof Durkalec-Michalski1, Jan Jeszka2.
Abstract
BACKGROUND: β-hydroxy-β-methylbutyric acid (HMB) is an interesting supplement in sports. However, literature sources present a limited number of studies that verify the efficacy of HMB intake over a longer time period among endurance athletes. For this reason, the aim of this study was to assess the effect of HMB supplementation on physical capacity, body composition and levels of biochemical markers in rowers.Entities:
Keywords: Adaptation; Rowing; Sport supplements; Training support; β-hydroxy-β-methylbutyric acid
Mesh:
Substances:
Year: 2015 PMID: 26225130 PMCID: PMC4518594 DOI: 10.1186/s12970-015-0092-9
Source DB: PubMed Journal: J Int Soc Sports Nutr ISSN: 1550-2783 Impact factor: 5.150
Characteristics of the participating rowers (n = 16)
| Study group | ||
|---|---|---|
| Parameter | Means ± SD | Range |
| Age (yr) | 19.5 ± 1.4 | 17.0 – 22.0 |
| Body mass (kg) | 87.3 ± 9.8 | 69.0 – 104.7 |
| Height (cm) | 187 ± 5 | 176 – 194 |
| FFM (kg) | 73.8 ± 6.4 | 63.9 – 83.4 |
| FM (kg) | 13.6 ± 5.3 | 5.1 –21.6 |
|
| 68.1 ± 6.4 | 58.4 – 75.0 |
| Peak power (W · kg−1) | 11.6 ± 1.1 | 9.9 – 13.2 |
| Years training (yr) | 8.2 ± 2.8 | 6 – 10 |
| Number of training sessions per week (session · week−1) | 8.6 ± 2.7 | 7 – 10 |
| Number of hours of training per week (h · week−1) | 16.8 ± 5.9 | 10 – 24 |
| Energy intake (kcal · kg−1 · day−1)a | 56.1 ± 14.2 | 37.0 – 79.2 |
| Protein intake (g · kg−1 · day−1)a | 1.6 ± 0.2 | 1.3 – 2.0 |
| Carbohydrate intake (g · kg−1 · day−1)a | 6.3 ± 1.4 | 4.9 – 9.3 |
| Fat intake (g · kg−1 · day−1)a | 1.7 ± 0.4 | 1.2 – 2.4 |
FFM fat-free mass, FM fat mass; maximal oxygen uptake
aMean energy and macronutrient intake during the supplementation period
Fig. 1A flow chart of the study design
Fig. 2Changes in fat mass after 12-week supplementation of HMB. Values are expressed as mean ± SD. Significant differences compared with placebo (independent samples t-tests) at: * p = 0.03
Levels of the monitored indices before and after the 12-week supplementation with HMB preparation and placebo
| Research period | PREHMB vs. PLA | HMB | Difference | PLACEBO | Difference | |
|---|---|---|---|---|---|---|
|
|
|
| ||||
| BM (kg) | Pre | 0.925 | 86.5 ± 9.3 | 0.016 | 86.2 ± 9.0 | 0.063 |
| Post | 84.6 ± 8.1 | 84.8 ± 8.5 | ||||
| FFM (kg) | Pre | 0.921 | 72.7 ± 6.3 | 0.117 | 72.9 ± 6.1 | 0.001 |
| Post | 71.7 ± 5.6 | 70.9 ± 5.7 | ||||
| FM (kg) | Pre | 0.755 | 13.8 ± 4.4 | 0.073 | 13.3 ± 4.7 | 0.197 |
| Post | 12.8 ± 4.0 | 14.1 ± 4.3 | ||||
|
| Pre | 0.681 | 5794 ± 676 | 0.240 | 5897 ± 735 | 0.067 |
| Post | 5905 ± 709 | 5723 ± 745 | ||||
|
| Pre | 0.572 | 67.3 ± 6.9 | 0.033 | 68.8 ± 8.0 | 0.438 |
| Post | 70.0 ± 6.9 | 67.8 ± 8.5 | ||||
| Tref (min) | Pre | 0.947 | 17.6 ± 3.1 | 0.043 | 17.7 ± 3.1 | 0.233 |
| Post | 19.0 ± 3.6 | 18.5 ± 3.7 | ||||
| Wmax (W) | Pre | 0.777 | 372 ± 52 | 0.052 | 378 ± 52 | 0.625 |
| Post | 397 ± 56 | 384 ± 60 | ||||
| Wmax (W · kg−1) | Pre | 0.621 | 4.31 ± 0.50 | 0.039 | 4.39 ± 0.41 | 0.234 |
| Post | 4.70 ± 0.55 | 4.55 ± 0.65 | ||||
| HRmax (bpm) | Pre | 0.962 | 185 ± 13 | 0.258 | 185 ± 9 | 0.136 |
| Post | 188 ± 9 | 188 ± 10 | ||||
| TVT (min) | Pre | 0.440 | 12.5 ± 2.1 | 0.003 | 12.8 ± 1.9 | 0.619 |
| Post | 13.7 ± 2.2 | 12.6 ± 2.6 | ||||
| WVT (W) | Pre | 0.187 | 278 ± 41 | 0.012 | 294 ± 36 | 0.310 |
| Post | 309 ± 42 | 284 ± 47 | ||||
| WVT (W · kg−1) | Pre | 0.248 | 3.24 ± 0.51 | 0.001 | 3.42 ± 0.32 | 0.554 |
| Post | 3.66 ± 0.36 | 3.36 ± 0.49 | ||||
| HRVT (bpm) | Pre | 0.399 | 157 ± 9 | 0.001 | 160 ± 10 | 0.598 |
| Post | 166 ± 11 | 161 ± 9 | ||||
| CK (U · L−1) | Pre | 0.865 | 328 ± 160 | 0.004 | 348 ± 169 | 0.008 |
| Post | 241 ± 103 | 265 ± 156 | ||||
| LDH (U · L−1) | Pre | 0.573 | 318 ± 36 | 0.033 | 326 ± 45 | 0.002 |
| Post | 302 ± 35 | 302 ± 39 | ||||
| Testosterone (mg · dL−1) | Pre | 0.895 | 510 ± 202 | 0.352 | 510 ± 154 | 0.569 |
| Post | 552 ± 160 | 487 ± 160 | ||||
| Cortisol (mg · dL−1) | Pre | 0.585 | 19.9 ± 5.3 | 0.331 | 20.0 ± 5.9 | 0.516 |
| Post | 20.6 ± 5.8 | 20.8 ± 4.1 | ||||
| T/C ratio (T · C−1*10−2) | Pre | 0.51 | 3.39 ± 1.77 | 0.53 | 3.36 ± 0.99 | 0.30 |
| Post | 3.41 ± 1.08 | 3.03 ± 1.11 | ||||
| Peak power (W) | Pre | 0.615 | 1003 ± 125 | 0.027 | 1028 ± 147 | 0.853 |
| Post | 1054 ± 116 | 1024 ± 122 | ||||
| Peak power (W · kg−1) | Pre | 0.488 | 11.65 ± 1.01 | 0.020 | 11.92 ± 1.16 | 0.960 |
| Post | 12.26 ± 0.83 | 11.91 ± 1.15 | ||||
| Average power (W) | Pre | 0.924 | 725 ± 87 | 0.648 | 722 ± 87 | 0.660 |
| Post | 720 ± 83 | 718 ± 82 | ||||
| Average power (W · kg−1) | Pre | 0.854 | 8.36 ± 0.60 | 0.688 | 8.32 ± 0.55 | 0.736 |
| Post | 8.30 ± 0.59 | 8.28 ± 0.65 | ||||
| Minimal power (W) | Pre | 0.478 | 503 ± 75 | 0.095 | 486 ± 52 | 0.763 |
| Post | 475 ± 54 | 491 ± 78 | ||||
| Minimal power (W · kg−1) | Pre | 0.465 | 5.80 ± 0.78 | 0.119 | 5.63 ± 0.55 | 0.821 |
| Post | 5.49 ± 0.53 | 5.67 ± 0.76 |
Values are expressed as mean ± SD
BM body mass, FFM fat-free mass, FM fat mass, maximal oxygen uptake, Tref exercise time before athlete’s refusal to continue exercising, Wmax maximum load, HRmax maximum heart rate, VT ventilatory threshold, T time to VT, W load at VT, HR heart rate at VT, CK creatine kinase, LDH lactate dehydrogenase, T/C ratio testosterone/cortisol ratio
aDepending on the data distribution: independent samples t-tests or Mann–Whitney U tests
bDepending on the data distribution: dependent samples t-tests or Wilcoxon-signed rank tests
Fig. 3Changes in maximal oxygen uptake and rates at ventilatory threshold after 12-week supplementation of HMB. Values are expressed as mean ± SD. Significant differences compared with placebo (independent samples t-tests) at: *- p = 0.03; † - p = 0.012, ‡ - p = 0.002; # - p < 0.001. : maximal oxygen uptake; TVT: time to VT; WVT: load at VT; HRVT: HR at VT